Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

<h4>Background</h4>Additional forms of pre-exposure prophylaxis are needed to prevent HIV-1 infection. 3BNC117 and 10-1074 are broadly neutralizing anti-HIV-1 antibodies that target non-overlapping epitopes on the HIV-1 envelope. We investigated the safety, tolerability, pharmacokinetics...

Full description

Bibliographic Details
Main Authors: Yehuda Z Cohen, Allison L Butler, Katrina Millard, Maggi Witmer-Pack, Rebeka Levin, Cecilia Unson-O'Brien, Roshni Patel, Irina Shimeliovich, Julio C C Lorenzi, Jill Horowitz, Stephen R Walsh, Shu Lin, Joshua A Weiner, Anna Tse, Alicia Sato, Chelsey Bennett, Bryan Mayer, Kelly E Seaton, Nicole L Yates, Lindsey R Baden, Allan C deCamp, Margaret E Ackerman, Michael S Seaman, Georgia D Tomaras, Michel C Nussenzweig, Marina Caskey
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0219142

Internet

https://doi.org/10.1371/journal.pone.0219142

Similar Items